Found: 33
Select item for more details and to access through your institution.
A decade of change: The evolution of pharmacy services at U.S. cystic fibrosis centers.
- Published in:
- Pediatric Pulmonology, 2024, v. 59, n. 3, p. 652, doi. 10.1002/ppul.26798
- By:
- Publication type:
- Article
Impact of pharmacy services on people with cystic fibrosis (PwCF) immunization rates.
- Published in:
- Pediatric Pulmonology, 2023, v. 58, n. 12, p. 3622, doi. 10.1002/ppul.26666
- By:
- Publication type:
- Article
Effective pharmacy provider handoff communication for transition of patient care in CF.
- Published in:
- Pediatric Pulmonology, 2023, v. 58, n. 8, p. 2394, doi. 10.1002/ppul.26464
- By:
- Publication type:
- Article
How many billions is enough? Prioritizing profits over patients with cystic fibrosis.
- Published in:
- Pediatric Pulmonology, 2023, v. 58, n. 5, p. 1595, doi. 10.1002/ppul.26335
- By:
- Publication type:
- Article
Implementation of a comprehensive pharmacy‐driven immunization care process model in a pediatric cystic fibrosis clinic.
- Published in:
- Pediatric Pulmonology, 2023, v. 58, n. 4, p. 1145, doi. 10.1002/ppul.26306
- By:
- Publication type:
- Article
The indispensable role of pharmacy services and medication therapy management in cystic fibrosis.
- Published in:
- Pediatric Pulmonology, 2022, v. 57, p. S17, doi. 10.1002/ppul.25613
- By:
- Publication type:
- Article
Optimization of antibiotics for cystic fibrosis pulmonary exacerbations due to highly resistant nonlactose fermenting Gram negative bacilli: Meropenem‐vaborbactam and cefiderocol.
- Published in:
- Pediatric Pulmonology, 2021, v. 56, n. 9, p. 3059, doi. 10.1002/ppul.25552
- By:
- Publication type:
- Article
State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary.
- Published in:
- Pediatric Pulmonology, 2021, v. 56, n. 7, p. 1825, doi. 10.1002/ppul.25353
- By:
- Publication type:
- Article
Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care.
- Published in:
- Pediatric Pulmonology, 2021, v. 56, n. 6, p. 1378, doi. 10.1002/ppul.25283
- By:
- Publication type:
- Article
Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins latest update.
- Published in:
- Pediatric Pulmonology, 2021, v. 56, n. 6, p. 1784, doi. 10.1002/ppul.25282
- By:
- Publication type:
- Article
Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: II. Therapies for allergic bronchopulmonary aspergillosis.
- Published in:
- Pediatric Pulmonology, 2020, v. 55, n. 12, p. 3541, doi. 10.1002/ppul.25080
- By:
- Publication type:
- Article
Impact of pharmacy technicians as part of an integrated health‐system pharmacy team on improvement of medication access in the care of cystic fibrosis patients.
- Published in:
- Pediatric Pulmonology, 2020, v. 55, n. 12, p. 3351, doi. 10.1002/ppul.25050
- By:
- Publication type:
- Article
State of the art in cystic fibrosis pharmacology—Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: I. Anti‐methicillin‐resistant Staphylococcus aureus (MRSA) antibiotics.
- Published in:
- Pediatric Pulmonology, 2020, v. 55, n. 1, p. 33, doi. 10.1002/ppul.24537
- By:
- Publication type:
- Article
Pancreatic insufficiency converted to pancreatic sufficiency with ivacaftor.
- Published in:
- Pediatric Pulmonology, 2019, v. 54, n. 11, p. 1654, doi. 10.1002/ppul.24454
- By:
- Publication type:
- Article
Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics.
- Published in:
- Pediatric Pulmonology, 2019, v. 54, n. 8, p. 1216, doi. 10.1002/ppul.24348
- By:
- Publication type:
- Article
Impact of pharmacy services on cystic fibrosis medication adherence: Update.
- Published in:
- Pediatric Pulmonology, 2018, v. 53, n. 6, p. 694, doi. 10.1002/ppul.23991
- By:
- Publication type:
- Article
Impact of pharmacy services on cystic fibrosis medication adherence.
- Published in:
- Pediatric Pulmonology, 2017, v. 52, n. 8, p. 1006, doi. 10.1002/ppul.23743
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update.
- Published in:
- Pediatric Pulmonology, 2017, v. 52, n. 7, p. 863, doi. 10.1002/ppul.23713
- By:
- Publication type:
- Article
Follow-up survey of the utilization of anti-pseudomonal beta-lactam antibiotics at U.S. cystic fibrosis centers.
- Published in:
- Pediatric Pulmonology, 2016, v. 51, n. 7, p. 668, doi. 10.1002/ppul.23350
- By:
- Publication type:
- Article
Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
- Published in:
- Pediatric Pulmonology, 2015, v. 50, n. 6, p. 552, doi. 10.1002/ppul.23132
- By:
- Publication type:
- Article
Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic fibrosis patients.
- Published in:
- Pediatric Pulmonology, 2014, v. 49, n. 3, p. 302, doi. 10.1002/ppul.22820
- By:
- Publication type:
- Article
The Use of Doripenem in Pediatric Cystic Fibrosis Patients in Case of Meropenem Shortages.
- Published in:
- Pediatric Pulmonology, 2014, v. 49, n. 3, p. E48, doi. 10.1002/ppul.22798
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
- Published in:
- Pediatric Pulmonology, 2013, v. 48, n. 11, p. 1047, doi. 10.1002/ppul.22813
- By:
- Publication type:
- Article
Intermittent and extended-infusion Beta-Lactam utilization in cystic fibrosis.
- Published in:
- Pediatric Pulmonology, 2013, v. 48, n. 6, p. 622, doi. 10.1002/ppul.22641
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
- Published in:
- Pediatric Pulmonology, 2013, v. 48, n. 6, p. 525, doi. 10.1002/ppul.22757
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
- Published in:
- Pediatric Pulmonology, 2013, v. 48, n. 3, p. 211, doi. 10.1002/ppul.22667
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.
- Published in:
- Pediatric Pulmonology, 2013, v. 48, n. 1, p. 1, doi. 10.1002/ppul.22664
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
- Published in:
- Pediatric Pulmonology, 2013, v. 48, n. 2, p. 107, doi. 10.1002/ppul.22669
- By:
- Publication type:
- Article
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems.
- Published in:
- Pediatric Pulmonology, 2012, v. 47, n. 12, p. 1147, doi. 10.1002/ppul.22655
- By:
- Publication type:
- Article
A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.
- Published in:
- Pediatric Pulmonology, 2011, v. 46, n. 10, p. 987, doi. 10.1002/ppul.21467
- By:
- Publication type:
- Article
Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients.
- Published in:
- Gastroenterology Research & Practice, 2011, v. 2011, p. 1, doi. 10.1155/2011/345012
- By:
- Publication type:
- Article
Population Pharmacokinetics of Intermittent Vancomycin in Children with Cystic Fibrosis.
- Published in:
- Pharmacotherapy, 2013, v. 33, n. 12, p. 1288, doi. 10.1002/phar.1320
- By:
- Publication type:
- Article
An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin‐Resistant Staphylococcus aureus.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 2, p. 198, doi. 10.1002/jcph.1323
- By:
- Publication type:
- Article